This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

CCI clears Advent International's Rs 3,150 crore investment in Yatharth Hospital

Advent International has officially secured the green light from the Competition Commission of India to channel an impressive Rs 3,150 crore into Yatharth Hospitals through its affiliate, Rasmalai Limited. Post-investment, Advent will own a 24.9 percent minority stake in the healthcare entity, which is poised to leverage this financial boost for its expansion efforts and enhancing its healthcare network amidst a backdrop of thriving operational revenues and profit growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ogpiknU
via IFTTT

Pharma industry steps up API investments to cut import dependence, move up value chain

India's pharmaceutical sector is shifting towards high-value medicines and reducing reliance on imports through local manufacturing. Investments in active pharmaceutical ingredients and advanced therapies are on the rise to meet new healthcare demands. Industry leaders highlight the significance of supply-chain resilience and advancements in manufacturing capabilities. Recent data indicates strong domestic market growth and increasing pharmaceutical exports.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hX7HyBe
via IFTTT

The man behind Lord’s Mark: Dr. Sachidanand Upadhyay features in TIME Magazine for the third consecutive year

Dr. Sachidanand Upadhyay has gained recognition from TIME Magazine for his remarkable contributions to technology and innovation. Lord’s Mark Industries Limited is spearheading key projects in healthcare, defence, and sustainability. With critical product registrations achieved, the company is poised for international growth. Upadhyay envisions transforming India into a prominent technology and manufacturing hub, emphasizing the importance of homegrown innovation in the global marketplace.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sA9Brbe
via IFTTT

Aayush Wellness reports 10.6% rise in first-half income

Aayush Wellness experienced an increase in consolidated income and profit for the first half of fiscal 2027. The company reported an impressive rise in both consolidated income and profit after tax. Standalone income also showed significant growth compared to the preceding quarter. Aayush Wellness is launching new products to expand its presence in preventive healthcare and nutraceutical markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pvcVQ2H
via IFTTT

Govt plans instant ban on manufacturing of drugs failing key quality tests

Pharma companies could have their drug licenses suspended immediately if quality tests indicate failure. The health ministry's proposed changes aim to protect public health by enforcing swift action on substandard medications. Regulators would take action upon receiving a government analyst's report declaring a drug not of standard quality. Manufacturers would need to perform a root cause analysis and implement corrective actions to lift the suspension.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JWATw2S
via IFTTT

Inside Park Hospitals' regional playbook: Why North India depth matters more than national reach

Park Hospitals is on an ambitious expansion journey, targeting around 6,600 beds by December 2028 across North India. Their strategy focuses on building hospitals in close proximity for better operational efficiency. The new Prayagraj initiative underscores a successful public-private partnership and illustrates their commitment to enhance healthcare capacity, ultimately improving patient care and resource management in the region.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XBV846w
via IFTTT

HRV Pharma buys Germany's Phatebo

The acquisition marks virtual pharmaceutical company HRV's entry beyond active pharmaceutical ingredients (APIs) into finished formulations, giving it its first finished formulations business alongside a licenced operating entity in Germany.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QKt3eqY
via IFTTT